Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Brentuximab Vedotin"" wg kryterium: Temat


Tytuł :
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
Autorzy :
Hutchings M; Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
Radford J; Manchester Academic Health Science Centre, University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.
Ansell SM; Mayo Clinic, Rochester, Minnesota, USA.
Illés Á; Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet and Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Connors JM; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.
Sýkorová A; University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
Shibayama H; Department of Hematology and Oncology, Osaka University, Osaka, Japan.
Abramson JS; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Chua NS; Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
Friedberg JW; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
Kořen J; First Faculty of Medicine, General University Hospital, Prague, Czech Republic.
LaCasce AS; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Molina L; CHU de Grenoble, Grenoble, France.
Engley G; Seattle Genetics, Bothell, Washington, USA.
Fenton K; Seattle Genetics, Bothell, Washington, USA.
Jolin H; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
Liu R; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
Gautam A; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
Gallamini A; Research and Innovation Department, Centre Antoine Lacassagne, Nice, France.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Apr; Vol. 39 (2), pp. 185-195. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Dacarbazine/*therapeutic use
Doxorubicin/*therapeutic use
Hodgkin Disease/*drug therapy
Neoplasm Staging/*methods
Vinblastine/*therapeutic use
Adult ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Brentuximab Vedotin/pharmacology ; Dacarbazine/pharmacology ; Doxorubicin/pharmacology ; Female ; Hodgkin Disease/pathology ; Humans ; Male ; Middle Aged ; Risk Factors ; Vinblastine/pharmacology
Czasopismo naukowe
Tytuł :
Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Autorzy :
Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Ogura M; Department of Hematology/Oncology, Kasugai Municipal Hospital, Kasugai, Japan.
Tobinai K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Hatake K; Department of Hematology, International University of Health and Welfare (IUHW) School of Medicine, Tokyo, Japan.; Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Sakamoto S; Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8668, Japan.
Nishimura M; Pharmacovigilance, Takeda Development Center Japan, Takeda Pharmaceutical Co. Ltd., Osaka, Japan.
Hoshino M; Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. .
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Mar; Vol. 113 (3), pp. 404-412. Date of Electronic Publication: 2021 Jan 03.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Antineoplastic Agents, Immunological/*adverse effects
Brentuximab Vedotin/*adverse effects
Hodgkin Disease/*drug therapy
Immunoconjugates/*adverse effects
Lymphoma, Large-Cell, Anaplastic/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/therapeutic use ; Brentuximab Vedotin/therapeutic use ; Female ; Humans ; Immunoconjugates/therapeutic use ; Japan ; Lung Diseases, Interstitial/chemically induced ; Lymphopenia/chemically induced ; Male ; Middle Aged ; Neutropenia/chemically induced ; Peripheral Nervous System Diseases/chemically induced ; Product Surveillance, Postmarketing ; Young Adult
Czasopismo naukowe
Tytuł :
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Autorzy :
Kuruvilla J; Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: .
Ramchandren R; Department of Medicine, University of Tennessee, Knoxville, TN, USA.
Santoro A; Humanitas University, Department of Biomedical Sciences, Milan, Italy.
Paszkiewicz-Kozik E; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Gasiorowski R; Concord Hospital, University of Sydney, Sydney, NSW, Australia.
Johnson NA; Jewish General Hospital Montreal, Montreal, QC, Canada.
Fogliatto LM; Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
Goncalves I; Fundação Pio XII-Hospital de Câncer de Barretos, São Paulo, Brazil.
de Oliveira JSR; Casa de Saude Santa Marcelina, São Paulo, Brazil.
Buccheri V; Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Perini GF; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Goldschmidt N; Hadassah Medical Center, Jerusalem, Israel.
Kriachok I; National Cancer Institute, Kiev, Ukraine.
Dickinson M; Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Komarnicki M; Szpital Kliniczny im Przemienienia, Poznań, Poland.
McDonald A; Pretoria East Hospital, Pretoria, South Africa.
Ozcan M; Ankara University School of Medicine, Ankara, Turkey.
Sekiguchi N; Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
Zhu Y; Concord Hospital, Merck & Co, Kenilworth, NJ, USA.
Nahar A; Concord Hospital, Merck & Co, Kenilworth, NJ, USA.
Marinello P; Concord Hospital, Merck & Co, Kenilworth, NJ, USA.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Pokaż więcej
Corporate Authors :
KEYNOTE-204 investigators
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Apr; Vol. 22 (4), pp. 512-524. Date of Electronic Publication: 2021 Mar 12.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Brentuximab Vedotin/*administration & dosage
Hodgkin Disease/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Brentuximab Vedotin/adverse effects ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hodgkin Disease/pathology ; Humans ; Immunoconjugates/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Progression-Free Survival ; Proportional Hazards Models ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.
Autorzy :
V Villarreal-Gonzalez R; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr. Jose Eleuterio Gonzalez', Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
N Gonzalez-Diaz S; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr. Jose Eleuterio Gonzalez', Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
E de Lira-Quezada C; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr. Jose Eleuterio Gonzalez', Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
Gómez-Almaguer D; Hematology Department, University Hospital 'Dr. Jose Eleuterio Gonzalez', Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
Gómez-De León A; Hematology Department, University Hospital 'Dr. Jose Eleuterio Gonzalez', Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
Acuña-Ortega N; Regional Center of Allergy and Clinical Immunology, University Hospital 'Dr. Jose Eleuterio Gonzalez', Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Mar; Vol. 27 (2), pp. 505-508. Date of Electronic Publication: 2020 Jul 19.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anaphylaxis/*therapy
Antineoplastic Agents/*adverse effects
Brentuximab Vedotin/*adverse effects
Desensitization, Immunologic/*methods
Drug Hypersensitivity/*therapy
Hodgkin Disease/*complications
Antineoplastic Agents/therapeutic use ; Brentuximab Vedotin/therapeutic use ; Epinephrine/therapeutic use ; Female ; Histamine Antagonists/therapeutic use ; Hodgkin Disease/drug therapy ; Humans ; Intradermal Tests ; Steroids/therapeutic use ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Autorzy :
Cheson BD; Lymphoma Research Foundation, New York, NY, USA. Electronic address: .
Bartlett NL; Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
LaPlant B; Division of Biomedical Statistics and Bioinformatics, Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN, USA.
Lee HJ; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Advani RJ; Stanford Cancer Institute, Stanford, CA, USA.
Christian B; Hematology Division, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Diefenbach CS; Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.
Feldman TA; Lymphoma Division, Hackensack University Medical Center, Hackensack, NJ, USA.
Ansell SM; Division of Medical Oncology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Nov; Vol. 7 (11), pp. e808-e815. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Hodgkin Disease/*drug therapy
Nivolumab/*therapeutic use
Aged ; Antineoplastic Agents, Immunological/adverse effects ; Brentuximab Vedotin/adverse effects ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Hematologic Diseases/diagnosis ; Hematologic Diseases/etiology ; Hodgkin Disease/mortality ; Hodgkin Disease/pathology ; Humans ; Injections, Intravenous ; Male ; Middle Aged ; Nivolumab/adverse effects ; Peripheral Nervous System Diseases/diagnosis ; Peripheral Nervous System Diseases/etiology ; Progression-Free Survival ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.
Autorzy :
Raymakers AJN; Health Economics Analytic Support and Research Unit (HEASRU), BC Cancer, Vancouver, Canada. .; Canadian Centre for Applied Research in Cancer Control (ARCC), BC Cancer Research Centre, 2nd floor, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada. .; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. .
Costa S; Canadian Centre for Applied Research in Cancer Control (ARCC), BC Cancer Research Centre, 2nd floor, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada.
Cameron D; Health Economics Analytic Support and Research Unit (HEASRU), BC Cancer, Vancouver, Canada.; Canadian Centre for Applied Research in Cancer Control (ARCC), BC Cancer Research Centre, 2nd floor, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada.
Regier DA; Health Economics Analytic Support and Research Unit (HEASRU), BC Cancer, Vancouver, Canada.; Canadian Centre for Applied Research in Cancer Control (ARCC), BC Cancer Research Centre, 2nd floor, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada.; School of Population and Public Health, University of British Columbia, Vancouver, Canada.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Oct 13; Vol. 20 (1), pp. 992. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*economics
Brentuximab Vedotin/*economics
Hodgkin Disease/*drug therapy
Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Brentuximab Vedotin/pharmacology ; Brentuximab Vedotin/therapeutic use ; Cost-Benefit Analysis ; Female ; Humans ; Male ; Probability
Czasopismo naukowe
Tytuł :
Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Autorzy :
Nikolaenko L; Department of Hematology/Bone Marrow Transplant, City of Hope, Duarte, CA 91010, USA.
Nademanee A; Department of Hematology/Bone Marrow Transplant, City of Hope, Duarte, CA 91010, USA.
Pokaż więcej
Źródło :
Future oncology (London, England) [Future Oncol] 2020 Oct; Vol. 16 (29), pp. 2273-2282. Date of Electronic Publication: 2020 Jul 17.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Hodgkin Disease/*drug therapy
Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Brentuximab Vedotin/administration & dosage ; Brentuximab Vedotin/adverse effects ; Disease Management ; Hodgkin Disease/diagnosis ; Hodgkin Disease/mortality ; Humans ; Ki-1 Antigen/antagonists & inhibitors ; Ki-1 Antigen/metabolism ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Autorzy :
Diefenbach CS; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Electronic address: .
Hong F; Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Biostatistics Center, Dana Farber Cancer Institute, Boston, MA, USA.
Ambinder RF; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Robertson MJ; School of Medicine, Indiana University, Bloomington, IN, USA.
David KA; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Jersey, NJ, USA.
Advani RH; Oncology Division, Stanford Cancer Institute, Stanford, CA, USA.
Fenske TS; Division of Hematology and Oncology, Froedtert and the Medical College of Wisconsin, Wauwatosa, WI, USA.
Barta SK; Divison of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Palmisiano ND; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Svoboda J; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Morgan DS; Vanderbilt University Medical Center, Nashville, TN, USA.
Karmali R; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, USA.
Sharon E; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethseda, MD, USA.
Streicher H; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethseda, MD, USA.
Kahl BS; School of Medicine, Washington University, St Louis, MO, USA.
Ansell SM; Division of Hematology, Mayo Clinic, Rochester MN, USA.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Sep; Vol. 7 (9), pp. e660-e670.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Hodgkin Disease/*drug therapy
Ipilimumab/*therapeutic use
Nivolumab/*therapeutic use
Adult ; Aged ; Antineoplastic Agents, Immunological/adverse effects ; Brentuximab Vedotin/adverse effects ; Disease Progression ; Drug Therapy, Combination ; Female ; Hodgkin Disease/mortality ; Hodgkin Disease/pathology ; Humans ; Hypersensitivity/etiology ; Ipilimumab/adverse effects ; Male ; Middle Aged ; Nivolumab/adverse effects ; Pain/etiology ; Progression-Free Survival ; Recurrence ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
Autorzy :
Koga Y; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Sekimizu M; Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Iguchi A; Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan.
Kada A; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Saito AM; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Asada R; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.; Innovative and Clinical Research Promotion Center, Graduate School of Medicine, Gifu University, Gifu, Japan.
Mori T; Department of Pediatrics, St. Marianna University School of Medicine Hospital, Kawasaki, Japan. .
Horibe K; Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2020 May; Vol. 111 (5), pp. 711-718. Date of Electronic Publication: 2020 Jan 20.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Ki-1 Antigen*
Brentuximab Vedotin/*administration & dosage
Hodgkin Disease/*drug therapy
Lymphoma, Large-Cell, Anaplastic/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Adolescent ; Asian Continental Ancestry Group ; Brentuximab Vedotin/adverse effects ; Brentuximab Vedotin/pharmacokinetics ; Child ; Child, Preschool ; Female ; Humans ; Infusions, Intravenous ; Male ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.
Autorzy :
Papakonstantinou I; Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Kosmidou M; Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Papathanasiou K; Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Koumpis E; Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Kapsali E; Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Milionis H; Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Vassilakopoulos TP; Department of Haematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papoudou-Bai A; Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Hatzimichael E; Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; .
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2021 Jul-Aug; Vol. 35 (4), pp. 1951-1957.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Cholestasis, Intrahepatic*
Hodgkin Disease*/complications
Hodgkin Disease*/diagnosis
Hodgkin Disease*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bleomycin ; Brentuximab Vedotin ; Dacarbazine/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Vinblastine/therapeutic use
Czasopismo naukowe
Tytuł :
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
Autorzy :
LaCasce AS; Dana-Farber Cancer Institute, Boston, MA, USA.
Bociek RG; University of Nebraska Medical Center, Omaha, NE, USA.
Sawas A; Columbia University Medical Center, New York, NY, USA.
Caimi P; University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Agura E; Charles A. Sammons Cancer Center, Dallas, TX, USA.
Matous J; Colorado Blood Cancer Institute, Denver, CO, USA.
Ansell SM; Mayo Clinic, Rochester, MN, USA.
Crosswell HE; St. Francis Hospital, Greenville, SC, USA.
Islas-Ohlmayer M; The Jewish Hospital-Mercy Health, Cincinnati, OH, USA.
Behler C; Pacific Hematology Oncology Associates, San Francisco, CA, USA.
Cheung E; The Oncology Institute of Hope & Innovation, Whittier, CA, USA.
Forero-Torres A; University of Alabama at Birmingham, Birmingham, AL, USA.
Vose J; University of Nebraska Medical Center, Omaha, NE, USA.
O'Connor OA; Columbia University Medical Center, New York, NY, USA.
Josephson N; Seattle Genetics, Inc, Bothell, WA, USA.
Wang Y; Seattle Genetics, Inc, Bothell, WA, USA.
Advani R; Stanford Cancer Institute, Stanford, CA, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (3), pp. e86-e90. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Bendamustine Hydrochloride/*therapeutic use
Brentuximab Vedotin/*therapeutic use
Hodgkin Disease/*drug therapy
Salvage Therapy/*methods
Antineoplastic Agents, Immunological/pharmacology ; Bendamustine Hydrochloride/pharmacology ; Brentuximab Vedotin/pharmacology ; Female ; Hodgkin Disease/mortality ; Humans ; Male ; Survival Analysis ; Time Factors ; Treatment Outcome
Raport
Tytuł :
Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.
Autorzy :
Gao S; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhang M; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Wu K; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhu J; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
He Z; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Li J; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Chen C; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Qiu K; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Yu X; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Wu J; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Pokaż więcej
Źródło :
Expert opinion on drug safety [Expert Opin Drug Saf] 2020 May; Vol. 19 (5), pp. 617-623. Date of Electronic Publication: 2020 Jan 24.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Agents, Immunological/*administration & dosage
Brentuximab Vedotin/*administration & dosage
Lymphoma/*drug therapy
Antineoplastic Agents, Immunological/adverse effects ; Brentuximab Vedotin/adverse effects ; Humans ; Lymphoma/pathology ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
Autorzy :
Sasapu A; Medicine, Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Dunn ALJ; Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Gardner J; Pathology, Geisinger Medical Laboratories, Danville, Pennsylvania, USA.
Wong HK; Dermatology, University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, USA .
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2021 Jul 21; Vol. 14 (7). Date of Electronic Publication: 2021 Jul 21.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Immunoconjugates*/therapeutic use
Lymphoma, Large-Cell, Anaplastic*/diagnosis
Lymphoma, Large-Cell, Anaplastic*/drug therapy
Lymphoma, Primary Cutaneous Anaplastic Large Cell*/drug therapy
Skin Neoplasms*/drug therapy
Brentuximab Vedotin ; Humans
Czasopismo naukowe
Tytuł :
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma.
Autorzy :
Zic JA; Department of Dermatology, VU Cutaneous Lymphoma Clinic, Vanderbilt University Medical Center, Vanderbilt Dermatology, One Hundred Oaks, 719 Thompson Lane, Suite 26300, Nashville, TN 37204-3609, USA. Electronic address: .
Pokaż więcej
Źródło :
The Medical clinics of North America [Med Clin North Am] 2021 Jul; Vol. 105 (4), pp. 737-755.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Lymphoma, T-Cell, Cutaneous/*diagnosis
Lymphoma, T-Cell, Cutaneous/*therapy
Skin Diseases/*diagnosis
Skin Neoplasms/*pathology
Aged ; Aged, 80 and over ; Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Arthropods ; Bexarotene/adverse effects ; Bites and Stings/diagnosis ; Brentuximab Vedotin/adverse effects ; Diagnosis, Differential ; Humans ; Hyperlipidemias/chemically induced ; Hypothyroidism/chemically induced ; Lymphoma, Primary Cutaneous Anaplastic Large Cell/diagnosis ; Lymphoma, T-Cell, Cutaneous/classification ; Lymphomatoid Papulosis/diagnosis ; Mycosis Fungoides/diagnosis ; Peripheral Nervous System Diseases/chemically induced ; Prognosis ; Sezary Syndrome/diagnosis ; Skin Diseases/pathology
Czasopismo naukowe
Tytuł :
A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma.
Autorzy :
Diehl LF; Duke University Medical Center, Durham, NC 27705, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Jun; Vol. 8 (6), pp. e384-e386.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Hodgkin Disease*/drug therapy
Brentuximab Vedotin ; Humans ; Vinblastine/therapeutic use ; Vincristine/therapeutic use
Czasopismo naukowe
Tytuł :
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.
Autorzy :
Longley J; Centre for Cancer Immunology, CRUK Research Centre, University of Southampton, Southampton, UK.
Johnson PWM; Centre for Cancer Immunology, CRUK Research Centre, University of Southampton, Southampton, UK.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Jun; Vol. 39 Suppl 1, pp. 39-45.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biomarkers, Tumor*/antagonists & inhibitors
Biomarkers, Tumor*/genetics
Biomarkers, Tumor*/metabolism
Hodgkin Disease*/drug therapy
Hodgkin Disease*/genetics
Hodgkin Disease*/metabolism
Hodgkin Disease*/pathology
Neoplasm Proteins*/antagonists & inhibitors
Neoplasm Proteins*/genetics
Neoplasm Proteins*/metabolism
Precision Medicine*
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
Programmed Cell Death 1 Receptor*/genetics
Programmed Cell Death 1 Receptor*/metabolism
Brentuximab Vedotin/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Autorzy :
Svoboda J; University of Pennsylvania, Philadelphia, PA, USA.
Bair SM; University of Pennsylvania, Philadelphia, PA, USA.
Landsburg DJ; University of Pennsylvania, Philadelphia, PA, USA.
Dwivedy Nasta S; University of Pennsylvania, Philadelphia, PA, USA.
Nagle SJ; Oregon Health and Science University, Portland, OR, USA.
Barta SK; University of Pennsylvania, Philadelphia, PA, USA.
Khan N; Fox Chase Cancer Center, Philadelphia, PA, USA.
Filicko-O'Hara J; Thomas Jefferson University, Philadelphia, PA, USA.
Gaballa S; Thomas Jefferson University, Philadelphia, PA, USA.
Strelec L; University of Pennsylvania, Philadelphia, PA, USA.
Chong E; University of Pennsylvania, Philadelphia, PA, USA.
Mitnick S; University of Pennsylvania, Philadelphia, PA, USA.
Waite TS; University of Pennsylvania, Philadelphia, PA, USA.
King C; University of Pennsylvania, Philadelphia, PA, USA.
Ballard H; University of Pennsylvania, Philadelphia, PA, USA.
Youngman M; University of Pennsylvania, Philadelphia, PA, USA.
Gerson J; University of Pennsylvania, Philadelphia, PA, USA.
Plastaras JP; University of Pennsylvania, Philadelphia, PA, USA.
Maity A; University of Pennsylvania, Philadelphia, PA, USA.
Bogusz AM; University of Pennsylvania, Philadelphia, PA, USA.
Hung SS; Centre for Lymphoid Cancer, Vancouver, BC, Canada.
Nakamura H; Centre for Lymphoid Cancer, Vancouver, BC, Canada.
Nejati R; Fox Chase Cancer Center, Philadelphia, PA, USA.
Steidl C; Centre for Lymphoid Cancer, Vancouver, BC, Canada.
Lim M; University of Pennsylvania, Philadelphia, PA, USA.
Ruella M; University of Pennsylvania, Philadelphia, PA, USA.
Schuster SJ; University of Pennsylvania, Philadelphia, PA, USA.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Jun 01; Vol. 106 (6), pp. 1705-1713. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Immunoconjugates*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Brentuximab Vedotin ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Ki-1 Antigen ; Prednisone/therapeutic use ; Rituximab/therapeutic use ; Treatment Outcome ; Vincristine/therapeutic use
Czasopismo naukowe
Tytuł :
Pembrolizumab for relapsed or refractory Hodgkin lymphoma.
Autorzy :
Pulsoni A; Department of Hematology, Sapienza University of Rome, Rome 00161, Italy. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Jun; Vol. 22 (6), pp. e234.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antineoplastic Agents, Immunological*/adverse effects
Hodgkin Disease*/drug therapy
Antibodies, Monoclonal, Humanized/adverse effects ; Brentuximab Vedotin ; Humans
Opinia redakcyjna
Tytuł :
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Autorzy :
Straus DJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Długosz-Danecka M; Department of Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Connors JM; Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Alekseev S; Petrov Research Institute of Oncology, St Petersburg, Russia.
Illés Á; University of Debrecen, Debrecen, Hungary.
Picardi M; Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Lech-Maranda E; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Feldman T; John Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA.
Smolewski P; Medical University of Lodz, Poland.
Savage KJ; Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Bartlett NL; Washington University School of Medicine Siteman Cancer Center, St Louis, MO, USA.
Walewski J; Maria Sklodowska-Curie National Research Institute of Oncology, European Reference Network, Warszawa, Poland.
Ramchandren R; The University of Tennessee Graduate School of Medicine, Knoxville, TN, USA.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Hutchings M; Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Munoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
Lee HJ; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kim WS; Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Advani R; Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.
Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Younes A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; AstraZeneca Pharmaceuticals, LP Wilmington, DE, USA.
Gallamini A; Research Innovation and Statistics, Antoine-Lacassagne Cancer Centre, Nice, France.
Liu R; Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, Cambridge, MA, USA.
Little M; Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, Cambridge, MA, USA.
Fenton K; Seagen, Bothell, WA, USA.
Fanale M; Seagen, Bothell, WA, USA.
Radford J; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Jun; Vol. 8 (6), pp. e410-e421.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Brentuximab Vedotin/*administration & dosage
Hodgkin Disease/*drug therapy
Bleomycin/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Follow-Up Studies ; Hodgkin Disease/mortality ; Hodgkin Disease/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Positron-Emission Tomography ; Progression-Free Survival ; Vinblastine/administration & dosage
Czasopismo naukowe
Tytuł :
Pembrolizumab for relapsed or refractory Hodgkin lymphoma - Author's reply.
Autorzy :
Kuruvilla J; Princess Margaret Cancer Centre, Toronto M5G 2M9, ON, Canada. Electronic address: .
Pokaż więcej
Corporate Authors :
KEYNOTE-204 investigators; Princess Margaret Cancer Centre, Toronto M5G 2M9, ON, Canada.
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Jun; Vol. 22 (6), pp. e235.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antineoplastic Agents, Immunological*/adverse effects
Hodgkin Disease*/drug therapy
Antibodies, Monoclonal, Humanized/adverse effects ; Brentuximab Vedotin ; Humans
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies